BusinessTESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMABy Nasdaq OMXOct 27, 2016, 8:10 PM UTC
BusinessTESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMABy Nasdaq OMXOct 27, 2016, 8:10 PM UTC
BusinessTESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016By Nasdaq OMXOct 8, 2016, 6:15 AM UTC
BusinessTESARO Announces Appointment of Dr. Kavita Patel to Board of DirectorsBy Nasdaq OMXApr 4, 2016, 12:00 PM UTC
BusinessTESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug AdministrationBy Nasdaq OMXMar 14, 2016, 12:05 PM UTC
BusinessTESARO Outlines Business Priorities and Strategic Outlook for 2016By Nasdaq OMXJan 11, 2016, 1:15 PM UTC
